Effects of Gluten Digestion With ALV003

NCT00859391 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2009-06-11

No results posted yet for this study

Summary

This is a Phase 0, Double-blind study that will assess the effect of in vitro treatment of gluten with ALV003 or with placebo when ingested by CD Subjects.

Conditions

Sponsors & Collaborators

  • Alvine Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Gregor Brown, MD · The Alfred

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00859391 on ClinicalTrials.gov